Welcome to our dedicated page for RECURSION PHARMACEUTICALS SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
A shareholder of RXRX has filed a notice to sell up to 100,000 Class A shares through Fidelity Brokerage Services, with an aggregate market value of $304,262.54, on or after July 21, 2026 on NASDAQ. The shares are identified as Founders Shares originally issued on April 20, 2021 as compensation. The filing also lists numerous prior Class A sales over the past three months by Christopher C. Gibson and related entities, including individual transactions as large as 340,440 shares.
A reporting person associated with RXRX filed a Form 144 indicating an intent to sell 100,000 Class A shares through Fidelity Brokerage Services on 07/20/2026, with an aggregate market value of $289,766.37. The notice identifies these as founders shares originally acquired on 04/20/2021 as compensation from the issuer. It also lists multiple prior Class A share sales over the past three months by Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC, each with specific dates, share amounts, and dollar proceeds.
RXRX shareholder Christopher C. Gibson filed to sell 100,000 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $296,725.90 and identifier 524677865, on NASDAQ as of 07/17/2026. The shares derive from Founders Shares originally issued on 04/20/2021 as compensation.
The filing also lists extensive Class A share sales in the prior three months by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, including individual transactions such as 340,440 shares for $1,089,541.29 on 06/18/2026 and multiple 100,000‑share sales on various July 2026 dates.
A Form 144 notice relates to a proposed sale of 100,000 Class A shares of the issuer through Fidelity Brokerage Services LLC on NASDAQ, with an approximate aggregate market value of 311064.87 and an approximate sale date of 07/16/2026.
The 100,000 shares were originally acquired on 04/20/2021 as “Founders Shares” from the issuer as compensation. The filing also lists multiple prior sales of Class A shares during the past three months by Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC, including transactions of 40,000, 100,000, 186,000, and 340,440 shares, each with disclosed aggregate sale prices.
A Form 144 notice for RXRX reports that Christopher C. Gibson plans to sell 123,334 Class A shares through Fidelity Brokerage Services LLC on or about July 15, 2026 on NASDAQ, with an aggregate market value of $410,282.60. These shares were acquired on April 20, 2021 as founder shares from the issuer as compensation.
The notice also lists numerous sales of Class A and Common shares during the prior three months by Christopher C. Gibson, Gibson Family Trust, and Lahwran-3 LLC, including individual transactions ranging from 40,000 to 340,440 shares and several 100,000‑share blocks between April 22 and July 14, 2026.
Shareholder Christopher C. Gibson plans to sell up to 100,000 Class A shares of RXRX through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of 330,472.68 and an approximate sale date of July 14, 2026. The notice also reports 524,677,865 Class A shares outstanding; this is a baseline figure, not the amount being sold.
The disclosure lists several Class A share sales over the past three months by Gibson and related entities, including 340,440 shares sold on June 18, 2026 for 1,089,541.29 and 186,000 shares sold on July 9, 2026 for 706,094.96.
Recursion Pharmaceuticals, Inc. (RXRX) filed a notice covering a proposed sale of 100,000 Class A shares through Fidelity Brokerage Services LLC on or after July 13, 2026. These are noted as founders shares originally acquired on April 20, 2021 as compensation.
The filing also lists multiple recent Class A share sales over the past three months by Christopher C. Gibson, the Gibson Family Trust, and Lahwran-3 LLC, with individual transactions ranging from 40,000 to 340,440 shares and corresponding dollar amounts disclosed for each sale.
RXRX shareholder Christopher C. Gibson filed a Form 144 to sell 100,000 Class A shares through Fidelity Brokerage Services LLC on July 10, 2026 on NASDAQ. The notice also lists multiple Class A share sales during the prior three months by Gibson, Gibson Family Trust, and Lahwran-3 LLC, each with specific share counts and dollar amounts.
RECURSION PHARMACEUTICALS, INC. director Blake Borgeson reported an open-market sale of Class A common stock. On July 7, 2026, he sold 40,000 shares at a weighted average price of about $3.96 per share. After this transaction, he directly holds 6,218,287 shares of the company.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. The shares were sold in multiple trades at prices ranging from $3.95 to $4.00, with the reported price reflecting the weighted average sale price.
Company and action: The filing reports disclosed sales of Class A shares by affiliates and individuals related to the Gibson family under Form 144. The excerpt lists multiple sale dates and share quantities, including individual transactions of 100,000 shares and a large block of 340,440 shares.
Context: Sales are reported with transaction dates from 04/22/2026 through 07/08/2026 and show aggregate per-line proceeds in dollars alongside each sale.